Skip to main
COYA
COYA logo

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is demonstrating progress in its clinical development, evidenced by a significant cognitive stabilization improvement of 4.93 points over placebo in ADAS-Cog scores, highlighting the potential of Treg modulation in Alzheimer's disease. The company's strategic investments and private placements have enhanced its cash position, enabling it to invest in clinical milestones that are anticipated for 2025. Coupled with rising partnerships such as the collaboration with Reddy's, Coya's strengthened financial foundation and commitment to a robust clinical pipeline position it favorably to advance its therapies aimed at neuroinflammation and drive long-term shareholder value.

Bears say

Coya Therapeutics faces significant challenges due to the historical failures associated with ALS drug development, which have been attributed to the disease's heterogeneity and ineffective clinical trial designs. Additionally, the indication that biweekly administration of LD IL-2 may lead to a weaker biological response raises concerns about the potential efficacy of their Treg therapies, further complicating their development strategy. Lastly, while Coya's combination therapy aims to tackle inflammation and immune regulation in ALS, the recent setbacks in the field highlight the risks of relying on a multi-target approach amidst prevalent uncertainties in therapeutic outcomes.

COYA has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 7 analysts, COYA has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.